You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
1 June 2023
Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model
27 March 2023
Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme
14 December 2022
Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept
19 October 2022
Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients
9 December 2021
Apogenix Receives EUR 20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19
22 December 2020
Apogenix AG: COVID-19 targeted treatment trial launched in Vienna